Need a wizard, or your local doctor?
I was intrigued to come across a
recent paper on immune modulatory treatments for autism by a couple of doctors from Massachusetts
General Hospital for Children. The lead
author has interests in:
· Autism spectrum disorders
· Psychopharmacology
· Developmental Disabilities
· Williams syndrome
· Angelman syndrome
· Down syndrome
Apparently,
he is an internationally-recognized expert in the neurobiology and
neuropsychopharmacology of childhood-onset neuropsychiatric disorders including
autistic disorder. Sounds promising, hopefully we will learn something
new.
The paper is actually a review of existing
drugs, with immunomodulatory properties, that have already been suggested to be
repurposed for autism. The abstract was not very insightful, so I have
highlighted the final conclusions and listed the drugs, by category, that they
thought should be investigated further.
All the drugs have already been
covered in this blog and have already been researched in autism.
One important point raised in the
conclusion relates to when the drugs are used.
Autism is a progressive condition early in life and there are so-called
“critical periods” when the developing brain is highly vulnerable.
For example, Pentoxifylline has been
found to be most effective in very young children. This does not mean do not give it to a
teenager with autism, it just means the sooner you treat autism the better the
result will be. This is entirely
logical.
Some very clever drugs clearly do not
work if given too late, for example Rapamycin analogs used in people with
TSC-type autism.
Multiple Critical Periods for Rapamycin Treatment to Correct Structural Defects in Tsc-1-Suppressed Brain
Importantly, each of these developmental abnormalities that are caused by enhanced mTOR pathway has a specific window of opportunity to respond to rapamycin. Namely, dyslamination must be corrected during neurogenesis, and postnatal rapamycin treatment will not correct the cortical malformation. Similarly, exuberant branching of basal dendrites is rectifiable only during the first 2 weeks postnatally while an increase in spine density responds to rapamycin treatment thereafter.
Back to today’s paper.
The
identification of immune dysregulation in at least a subtype ASD has led to the
hypothesis that immune modulatory treatments may be effective in treating the
core and associated symptoms of ASD. In this article, we discussed how currently FDA-approved
medications for ASD have immune modulatory properties.
“Risperidone also inhibited the expression of inflammatory
signaling proteins, myelin basic protein isoform 3 (MBP1) and mitogen-activated
kinase 1 (MAPK1), in a rat model of MIA. Similarly, aripiprazole has been
demonstrated to inhibit expression of IL-6 and TNF-α in cultured primary human
peripheral blood mononuclear cells from healthy adult donors.”
We then described emerging treatments for
ASD which have been repurposed from nonpsychiatric fields of medicine including
metabolic disease, infectious disease, gastroenterology, neurology, and
regenerative medicine, all with immune modulatory potential. Although immune modulatory treatments are not
currently the standard of care for ASD, remain experimental, and require
further research to demonstrate clear safety, tolerability, and efficacy, the
early positive results described above warrant further research in the context
of IRB-approved clinical trials. Future research is needed to determine whether
immune modulatory treatments will affect underlying pathophysiological
processes affecting both the behavioral symptoms and the common immune-mediated
medical co-morbidities of ASD. Identification of neuroimaging or inflammatory biomarkers
that respond to immune modulatory treatment and correlate with treatment
response would further support the hypothesis of an immune-mediated subtype of
ASD and aid in measuring response to immune modulatory treatments. In addition, it will be important
to determine if particular immune modulating treatments are best tolerated and most effective when
administered at specific developmental time points across the lifespan of
individuals with ASD.
1. Metabolic disease
Spironolactone
Pioglitazone
Pentoxifylline
Spironolactone is a cheap potassium sparing diuretic. It has secondary
effects that include reducing the level of male hormones and some inflammatory
cytokines.
Pioglitazone is drug for type 2 diabetes that improves insulin
sensitivity. It reduces certain
inflammatory cytokines making it both an autism therapy and indeed a suggested
Covid-19 therapy.
Pentoxifylline is a non-selective phosphodiesterase
(PDE) inhibitor, used to treat muscle
pain. PDE
inhibitors are very interesting drugs with a great therapeutic potential for
the treatment of immune-mediated and inflammatory diseases. Roflumilast and Ibudilast are PDE4 inhibitors
that also may improve some autism. The
limiting side effect can be nausea/vomiting, which can happen with
non-selective PDE4 inhibitors.
I did try Spironolactone once; it did not seem to have any
effect. It is a good match for
bumetanide because it increases potassium levels.
I do think that Pioglitazone has a helpful effect and there will
be another post on that.
PDE inhibitors are used by readers of this blog. Maja is a fan of
Pentoxifylline, without any side effects. Roflumilast at a low dose is supposed
to raise IQ, but still makes some people want to vomit. The Japanese drug
Ibudilast works for some, but nausea is listed as a possible side effect.
2. Infectious disease
Minocycline
Vancomycin
Suramin
Minocycline is an antibiotic that crosses in to the brain. It is known to stabilize activated microglia,
the brain’s immune cells. It is also
known that tetracycline
antibiotics are immunomodulatory.
Vancomycin is an
antibiotic used to treat bacterial infections, if taken orally it does not go
beyond the gut. It will reduce the level
of certain harmful bacteria including Clostridium
difficile.
Suramin is an anti-parasite drug that Dr
Naviaux is repurposing for autism, based on his theory of cell danger response.
3. Neurology
Valproic
acid
Valproic acid is an anti-epileptic drug.
It also has immunomodulatory and HDAC effects, these effects can both
cause autism when taken by a pregnant mother and also improve autism in some
people.
Valproic acid can have side effects. Low dose valproic acid seems to
work for some people.
4. Gastroenterology
Fecal
microbiota transplant (FMT)
FMT is currently used to
treat recurrent Clostridium difficile infection and may also be of benefit for
other GI conditions including IBD, obesity, metabolic syndrome, and functional
GI disorders.
Altered gut bacteria (dysbiosis) is a
feature of some autism which then impairs brain function. Reversing the dysbiosis with FMT improves
brain function.
5. Oncology
Lenalidomide
Romidepsin
Lenalidomide is an expensive anti-cancer drug that also has
immunomodulatory effects.
Romidepsin is a potent HDAC inhibitor, making it a useful cancer
therapy. HDAC inhibitors are potential
autism drugs, but only if given early enough not to miss the critical periods
of brain development.
6. Pulmonology
N-acetylcysteine
Many people with autism respond well to NAC. You do need a lot of
it, because it has a short half-life.
7. Nutritional
medicine and dietary supplements
Omega-3
fatty acids
Vitamin
D
Flavonoids
Nutritional supplements can get very expensive. In hot climates, like Egypt, some dark
skinned people cover up and then lack vitamin D. A lack of vitamin D will make autism worse.
Some people with mild brain disorders do seem to benefit from some
omega-3 therapies.
Flavonoids are very good for general health, but seem to lack potency
for treating brain disorders. Quercetin
and luteolin do have some benefits.
8. Rheumatology
Celecoxib
Corticosteroids
Intravenous
immunoglobulin (IVIG)
Celecoxib is a common NSAID that is particularly well tolerated
(it affects COX-2 and only marginally COX-1, hence its reduced GI side
effects).
NSAIDS are used by many people with autism.
Steroids do improve some people’s autism, but are unsuitable for
long term use. A short course of
steroids reduces Covid-19 deaths – a very cost effective therapy.
IVIG is extremely expensive, but it does provide a benefit in some
cases. IVIG is used quite often to treat autism in the US, but rarely elsewhere
other than for PANS/PANDAS that might occur with autism.
9. Regenerative
medicine
Stem
cell therapy
I was surprised they gave stem cell
therapy a mention. I think it is still early days for stem cell therapy.
Conclusion
I have observed the ongoing Covid-19
situation with interest and in particular what use has been made of the
scientific literature.
There are all sorts of interesting
snippets of data. You do not want to be deficient in Zinc or vitamin D, having
high cholesterol will make it easier for the virus to enter your cells. Potassium levels may plummet and blood becomes sticky, so may form dangerous clots. A long list of drugs may be at least
partially effective, meaning they speed up recovery and reduce death rates.
Polytherapy, meaning taking multiple drugs, is likely to be the best choice for
Covid-19.
Potential side effects of some drugs
have been grossly exaggerated, as with drugs repurposed for autism. Even in published research, people cheat and
falsify the data. In the case of hydroxychloroquine, the falsified papers were quickly
retracted.
The media twist the facts, to suit
their narrative, as with autism. This happens even with
Covid-19. Anti-Trump media (CNN, BBC etc) is automatically anti-hydroxychloroquine,
and ignores all the published research and the results achieved in countries
that widely use it (small countries like China and India).
Shutting down entire economies when only 5-10% of the population have been infected and hopefully got some immunity, does not look so smart if you are then going to reopen and let young people loose. They will inevitably catch the virus and then infect everyone else. Permanent lockdown restrictions, if followed by everyone, until a vaccine which everyone actually agreed to take, makes sense and living with the virus makes sense, but anything in between is not going to work. After 3 months without any broad lockdown, and allowing young people to socialize, most people would have had the virus and then those people choosing to shield could safely reemerge. The death rate with the current optimal, inexpensive treatment, as used in India or South Africa is very low, in people who are not frail to start with. Time to make a choice. Poor people in poor countries cannot afford to keep going into lockdown, they need to eat.
Shutting down entire economies when only 5-10% of the population have been infected and hopefully got some immunity, does not look so smart if you are then going to reopen and let young people loose. They will inevitably catch the virus and then infect everyone else. Permanent lockdown restrictions, if followed by everyone, until a vaccine which everyone actually agreed to take, makes sense and living with the virus makes sense, but anything in between is not going to work. After 3 months without any broad lockdown, and allowing young people to socialize, most people would have had the virus and then those people choosing to shield could safely reemerge. The death rate with the current optimal, inexpensive treatment, as used in India or South Africa is very low, in people who are not frail to start with. Time to make a choice. Poor people in poor countries cannot afford to keep going into lockdown, they need to eat.
What hope is there for treating a
highly heterogeneous condition like autism, if it is not approached entirely
rationally and without preconceptions and preconditions? In a pandemic we see that science does not drive policy and translating science into therapy is highly variable. The science is there for those who choose to read it.
I frequently see comments from parents
who have seen some of the research showing that autism has an inflammatory/auto-immune
component. They ask why this has not
been followed up on in the research. It
has been followed up on. It just has not
been acted upon.
Why has it not been acted on?
This missing stage is called
“translation”. Why don’t doctors
translate scientific findings into therapy for their patients?
What is common sense to some, is
“experimental” to others. “Experimental” is frowned upon in modern medicine,
but innovation requires experimentation.
Many people’s severe autism is unique
and experimental polytherapy/polypharmacy is their only hope.
The cookie cutter approach is not
going to work for autism.
Thankfully, for many common diseases
the cookie cutter approach works just fine.
Do the authors of today’s paper, Dr
McDougle and Dr Thom, actually prescribe to their young patients many of the
drugs that they have written about? I
doubt it and therein lies the problem.
Time for that wizard, perhaps?
A few years ago I did add the following tag line, under the big Epiphany at the top of the page.
An Alternative Reality for Classic Autism - Based on Today's Science
You can choose a different Autism reality, if you do not like your current one. I am glad I did. I didn't even need a wizard.
There are many immuno-modulatory therapies for autism that the Massachusetts doctor duo did not mention, but it is good that they made a start.
There are many immuno-modulatory therapies for autism that the Massachusetts doctor duo did not mention, but it is good that they made a start.